Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Matching expected patterns confirms genuine peptide rather than synthetic mimics or contaminants
As approved indications continue to broaden, and adoption scales in those with established disease, the cumulative impact on public health could be profound
FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
Use in Ascites Management Beyond Liver Cirrhosis Frusemide and Spironolactone are also employed in the management of ascites resulting from conditions other than liver cirrhosis, such as heart failure or malignancy, providing a critical component of palliative care
